CSIMarket
 


Cryoport inc   (CYRX)
Other Ticker:  
 

Cryoport Inc 's Long Term Debt to Equity

CYRX's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Due to net new long-term borrowings of 0.43%, Long Term Debt to Equity fell to 0.78, above the Cryoport Inc 's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 37 other companies have achieved lower Long Term Debt to Equity than Cryoport Inc in the IV Quarter 2023. While Long Term Debt to Equity total ranking has improved so far in the forth quarter 2023 to 1163, from total ranking in the third quarter 2023 at 1708 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt CYRX´s has?
What is the structure of CYRX´s Equity?


CYRX Long Term Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -12.02 % -3.27 % -4.25 % -8.03 % -13.4 %
Y / Y Long Term Debt Change -6.68 % -6.93 % 0.62 % 0.46 % 0.45 %
Long Term Debt to Equity MRQ 0.78 0.7 0.75 0.73 0.73
CYRX's Total Ranking # 1163 # 1708 # 1829 # 1876 # 2025
Seq. Equity Change -9.02 % -1.24 % -2.9 % 0.84 % 0.02 %
Seq. Long Term Debt Change 0.43 % -7.37 % 0.15 % 0.16 % 0.16 %



Long Term Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 121
Overall Market # 1162


Long Term Debt to Equity Statistics
High Average Low
0.93 0.54 0.13
(Sep 30 2020)   (Sep 30 2019)




Financial Statements
Cryoport Inc 's Equity $ 489 Millions Visit CYRX's Balance sheet
Cryoport Inc 's Long Term Debt $ 380 Millions Visit CYRX's Balance sheet
Source of CYRX's Sales Visit CYRX's Sales by Geography


Cumulative Cryoport Inc 's Long Term Debt to Equity

CYRX's Long Term Debt to Equity for the trailling 12 Months

CYRX Long Term Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -12.02 % -3.27 % -4.25 % -8.03 % -13.4 %
Y / Y Long Term Debt TTM Growth -6.68 % -6.93 % 0.62 % 0.46 % 0.45 %
Long Term Debt to Equity TTM 0.74 0.73 0.74 0.73 0.71
Total Ranking TTM # 1132 # 78 # 112 # 1764 # 90
Seq. Equity TTM Growth -9.02 % -1.24 % -2.9 % 0.84 % 0.02 %
Seq. Long Term Debt TTM Growth 0.43 % -7.37 % 0.15 % 0.16 % 0.16 %


On the trailing twelve months basis Due to the net new long-term borrowings of 0.43% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLong Term Debt to Equity improved to 0.74, a new company high.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 43, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Cryoport Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 78 to 1132.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt CYRX´s has?
What is the structure of CYRX´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 129
Within the Market # 1132


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.74 0.4 0.06
(Dec 31 2023)   (Mar 31 2020)




Companies with similar Long Term Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityDec 31 2023 MRQ Long Term DebtDec 31 2023 MRQ Equity
Blueprint Medicines Corporation  1.90 $ 247.733  Millions$ 130.609  Millions
Travere Therapeutics Inc   1.88 $ 377.263  Millions$ 200.810  Millions
Eli Lilly And Company  1.69 $ 18,320.800  Millions$ 10,863.700  Millions
Phibro Animal Health Corporation  1.66 $ 448.853  Millions$ 270.803  Millions
Ionis Pharmaceuticals Inc  1.56 $ 604.121  Millions$ 386.686  Millions
G1 Therapeutics Inc   1.46 $ 51.557  Millions$ 35.386  Millions
Alimera Sciences Inc   1.40 $ 64.489  Millions$ 46.170  Millions
Jazz Pharmaceuticals Plc  1.37 $ 5,107.988  Millions$ 3,736.997  Millions
Catalent Inc   1.34 $ 4,959.000  Millions$ 3,687.000  Millions
Xoma Corporation  1.34 $ 118.518  Millions$ 88.721  Millions
Zoetis Inc   1.32 $ 6,564.000  Millions$ 4,991.000  Millions
Summit Therapeutics Inc   1.29 $ 100.000  Millions$ 77.692  Millions
Bristol myers Squibb Company  1.24 $ 36,653.000  Millions$ 29,485.000  Millions
Elanco Animal Health Inc  0.92 $ 5,736.000  Millions$ 6,223.000  Millions
Merck and Co Inc   0.89 $ 33,683.000  Millions$ 37,635.000  Millions
Ocular Therapeutix Inc   0.82 $ 74.925  Millions$ 91.131  Millions
Viatris Inc   0.79 $ 16,188.100  Millions$ 20,467.400  Millions
Cryoport inc   0.78 $ 379.888  Millions$ 489.023  Millions
Perrigo Company Plc  0.76 $ 3,632.800  Millions$ 4,767.900  Millions
Prestige Consumer Healthcare Inc   0.75 $ 1,199.340  Millions$ 1,600.577  Millions
Verastem inc   0.70 $ 40.086  Millions$ 57.374  Millions
Pfizer Inc  0.69 $ 61,538.000  Millions$ 89,288.000  Millions
Emergent Biosolutions Inc   0.69 $ 446.500  Millions$ 649.300  Millions
Ani Pharmaceuticals Inc  0.66 $ 284.819  Millions$ 432.749  Millions
Mersana Therapeutics Inc   0.63 $ 23.148  Millions$ 36.904  Millions
Royalty Pharma Plc  0.61 $ 6,135.285  Millions$ 10,084.289  Millions
Aytu Biopharma Inc   0.46 $ 14.978  Millions$ 32.853  Millions
Cumberland Pharmaceuticals Inc  0.44 $ 12.784  Millions$ 29.260  Millions
Soligenix inc   0.40 $ 1.011  Millions$ 2.522  Millions
Harmony Biosciences Holdings inc   0.38 $ 178.566  Millions$ 466.992  Millions

Date modified: 2024-03-13T23:04:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com